Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabotegravir

FDA-approved product (suspension, extended release, intramuscular), marketed as Apretude, Vocabria.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabotegravir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabotegravir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabotegravir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

    NCT06133686 · start 2024-04-01

    Registered record
    Registry ID
    NCT06133686
    Conditions
    HIV
    Interventions
    Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA); Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2024-04-01
    Completion
    2027-04-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA); Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

    NCT06273943 · start 2024-04-01

    Registered record
    Registry ID
    NCT06273943
    Conditions
    Prevention
    Interventions
    Cabotegravir Tablets, for oral use.; Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.; Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use; Rectal Biopsies
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2024-04-01
    Completion
    2026-10-30
    Enrolment
    322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrevention
    InterventionCabotegravir Tablets, for oral use.; Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.; Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use; Rectal Biopsies
    PhasePhase 3
    Registry statusNot yet recruiting

  • Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT

    NCT06250504 · start 2024-02-27

    Registered record
    Registry ID
    NCT06250504
    Conditions
    HIV Infections
    Interventions
    APRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring; tenofovir disoproxil and emtricitabine; Tenofovir Disoproxil, Lamuvidine and Dolutegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-02-27
    Completion
    2026-10
    Enrolment
    2,052

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAPRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring; tenofovir disoproxil and emtricitabine; Tenofovir Disoproxil, Lamuvidine and Dolutegravir
    PhasePhase 3
    Registry statusRecruiting

  • Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

    NCT06145854 · start 2024-01-02

    Registered record
    Registry ID
    NCT06145854
    Conditions
    Hiv
    Interventions
    Cabotegravir Injection [Apretude]
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-01-02
    Completion
    2027-03-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionCabotegravir Injection [Apretude]
    PhaseNot recorded
    Registry statusActive not recruiting

  • Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

    NCT06185452 · start 2023-09-26

    Registered record
    Registry ID
    NCT06185452
    Conditions
    HIV-1 Infection
    Interventions
    Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration; Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-09-26
    Completion
    2025-05-30
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionHospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration; Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration
    PhasePhase 4
    Registry statusCompleted

  • A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

    NCT05996471 · start 2023-08-17

    Registered record
    Registry ID
    NCT05996471
    Conditions
    HIV Infections
    Interventions
    VH3810109; Cabotegravir; Standard of care (SOC); rHuPH20
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-08-17
    Completion
    2028-11-09
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionVH3810109; Cabotegravir; Standard of care (SOC); rHuPH20
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

    NCT05917509 · start 2023-07-06

    Registered record
    Registry ID
    NCT05917509
    Conditions
    HIV Infections
    Interventions
    DTG/3TC; Cabotegravir (CAB) LA; Rilpivirine (RPV) LA
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-07-06
    Completion
    2026-04-20
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDTG/3TC; Cabotegravir (CAB) LA; Rilpivirine (RPV) LA
    PhasePhase 3
    Registry statusCompleted

  • The CATALYST Study

    NCT05937698 · start 2023-05-30

    Registered record
    Registry ID
    NCT05937698
    Conditions
    HIV Prevention
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2023-05-30
    Completion
    2025-01-27
    Enrolment
    6,069

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

    NCT05867212 · start 2023-05-13

    Registered record
    Registry ID
    NCT05867212
    Conditions
    HIV Infections
    Interventions
    Cabotegravir Injection [Apretude]
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-05-13
    Completion
    2025-04-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir Injection [Apretude]
    PhaseNot recorded
    Registry statusCompleted

  • SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

    NCT05549726 · start 2023-01-02

    Registered record
    Registry ID
    NCT05549726
    Conditions
    HIV
    Interventions
    Cabotegravir Injectable Suspension; Dynamic Choice Delivery Model; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-01-02
    Completion
    2025-01-30
    Enrolment
    984

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionCabotegravir Injectable Suspension; Dynamic Choice Delivery Model; Standard of Care
    PhasePhase 4
    Registry statusCompleted

  • The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

    NCT05515770 · start 2022-09-20

    Registered record
    Registry ID
    NCT05515770
    Conditions
    HIV Infections
    Interventions
    Cabotegravir Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-09-20
    Completion
    2026-02
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir Injection
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

    NCT05418868 · start 2022-06-14

    Registered record
    Registry ID
    NCT05418868
    Conditions
    HIV Infections
    Interventions
    Cabotegravir 200 mg/mL; Cabotegravir >=400 mg/mL; Cabotegravir Formulation I; CAB Formulation J; rHuPH20; RPV
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2022-06-14
    Completion
    2027-06-08
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCabotegravir 200 mg/mL; Cabotegravir >=400 mg/mL; Cabotegravir Formulation I; CAB Formulation J +2 more
    PhasePhase 1
    Registry statusRecruiting

  • Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)

    NCT05152953 · start 2022-06-08

    Registered record
    Registry ID
    NCT05152953
    Conditions
    Hiv
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-06-08
    Completion
    2023-11-15
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

    NCT05374525 · start 2022-05-18

    Registered record
    Registry ID
    NCT05374525
    Conditions
    HIV Infections
    Interventions
    APRETUDE; Cabotegravir OLI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-05-18
    Completion
    2024-08-08
    Enrolment
    287

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAPRETUDE; Cabotegravir OLI
    PhasePhase 4
    Registry statusCompleted

  • Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

    NCT06405464 · start 2022-03-01

    Registered record
    Registry ID
    NCT06405464
    Conditions
    HIV Infections
    Interventions
    VOCABRIA 30Mg Tablet; EDURANT 25Mg Tablet; Cabotegravir Injectable Suspension; Rilpivirine Injectable Suspension; Intact proviral DNA assay; Full-length sequencing
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-03-01
    Completion
    2026-06-30
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionVOCABRIA 30Mg Tablet; EDURANT 25Mg Tablet; Cabotegravir Injectable Suspension; Rilpivirine Injectable Suspension +2 more
    PhaseNot recorded
    Registry statusUnknown